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The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was first occurred in China in December 2019 and subsequently spread all over
the world with cardiovascular, renal, and pulmonary symptoms. Therefore, recog-
nizing and treating the cardiovascular sign and symptoms that caused by corona-
virus disease 2019 (COVID-19) can be effective in reducing patient mortality. To
control the COVID-19-related cardiovascular symptoms, natural products are
considered one of the promising choices as complementary medicine. Scientists
are struggling to discover new antiviral agents specific to this virus. In this review,
the natural products for management of cardiovascular symptoms of COVID-19
are categorized into three groups: (a) natural products with an impact on angio-
tensin II type 1 receptor; (b) natural products that inhibit angiotensin-converting
enzyme activity; and (c) natural products that mimic adenosine activity. All these
natural products should undergo clinical investigations to test their efficacy,
safety, and toxicity in the treatment of cardiovascular symptoms of COVID-19.
This article summarizes agents with potential efficacy against COVID-19-related
cardiovascular symptoms.
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1 | INTRODUCTION
Since the end of December 2019, a new severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) (Huang et al., 2020; Wu
et al., 2020) that has affected countries around the world. Overall, coro-
navirus disease of 2019 (COVID-19) is an acute disease that can cause
2% mortality. Symptoms such as progressive respiratory failure and
massive alveolar damage may be the cause of death in severe cases of
the disease (Chan et al., 2020; Xu, Shi, et al., 2020). Preliminary efforts
have concentrated on identifying, counting patients, and describing the
clinical terms, and treating patients. The COVID-19 infection led to
series of severe respiratory illness similar to severe acute respiratory
syndrome coronavirus and was correlated with intensive care unit
admission and high mortality (Huang et al., 2020). Additionally, the risk
of death from COVID-19 may be higher in patients with cardiovascular
disease (CVD) (Huang et al., 2020). Therefore, recognizing and treating
the cardiovascular symptoms caused by coronavirus can be effective in
managing this disease and decreasing the mortality rate. In this regard,
natural products show a critical role as nutraceutical supplements and
provide prospective health benefits in CVD. Compilation of data from
epidemiological, experimental, and clinical trial studies point out that
natural products have substantial cardioprotective impact in the pre-
vention of CVD, therefore these are considered as cardiovascular-
friendly natural products. At this point in time, there is an urgent need
to cure and control all the symptom of SARS-CoV-2 infections, espe-
cially cardiovascular symptoms. In this review, the impact of natural
product on managing the cardiovascular sequels of SARS-CoV-2 infec-
tions are highlighted.
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2 | MECHANISM OF ENTRANCE OF
COVID-19
The spike (S) protein in coronaviruses comforts the entry of viruses into
target cells. This entry depends on the binding of the surface unit S1 of
S protein of a cellular receptor that helps viral attachment to the sur-
face of target cells. In addition, the entry requires S protein priming by
cellular proteases, which entail S protein cleavage at the S1/S2 and the
S2 site and allow fusion of viral and cellular membranes, a process
driven by the S2 subunit (Hoffmann et al., 2020). SARS-S engages
angiotensin-converting enzyme 2 (ACE2) as the entry receptor
(Li et al., 2003) via activation of the S protein by trans membrane prote-
ase serine 2 (TMPRSS2) (Clerkin et al., 2020). The expression of ACE2
mRNA is presented in human carotid atherosclerotic lesions. Further-
more, ACE2 protein is presented in nondiseased mammary arteries and
atherosclerotic carotid arteries, human veins, endothelial cells, smooth
muscle cells, macrophages (Sluimer et al., 2008), oral mucosa epithelial
cells (Xu, Zhong, et al., 2020), and renal cells (Wu, et al., 2020). In order
to investigate the infection caused by COVID-19 in human, organs such
as lung, heart, esophagus, kidney, bladder, and ileum, as well as specific
cells, particularly myocardial cells, type II alveolar cells, proximal tubule
cells and bladder urothelial cells, esophagus and ileum epithelial cells
are vulnerable for COVID-19 infection (Zou et al., 2020).
Since ACE2 is an important COVID-19 receptor, the binding of S
protein of COVID-19 to ACE2 reduces its expression, and as a result,
the ACE2 expression reduction causes acute respiratory failure (Kuba
et al., 2005). The number of ACE2 is high in the heart, which is the result
of angiotensin II in over activation of the renin-angiotensin system (RAS)
in states like congestive heart failure, atherosclerosis, and hypertension
(Tikellis & Thomas, 2012). In addition to the lung and heart, ACE2 is
expressed in the vascular endothelium, kidneys, and the intestinal epi-
thelium, leading to a mode of action to disrupt the function of several
organs, causing COVID-19 infection (Tikellis & Thomas, 2012; Zhang,
Penninger, Li, Zhong, & Slutsky, 2020). Evidence from clinical trials in
patients with COVID-19 indicates that mortality from the disease is
higher in people with CVD. Natural products are one of the most popu-
lar options for prevention, control, and treatment of the disease
throughout the globe and widely grasped as an adjunct treatment to
conventional therapy. Growing public awareness and scientific enthusi-
asm have conducted studies toward the importance of natural products
in disease treatment and health promotion. On the other hand, natural
products in the form of nutraceuticals ameliorate cardiovascular symp-
toms, as evidenced by various epidemiological, experimental and clinical
trial studies (Shukla, Gupta, Ojha, & Sharma, 2010). Hence, in this
review, we study the pharmacological activity of natural products for
the management of cardiovascular symptoms of COVID-19.
3 | THE FUNCTION OF ACE, ACE 2, AND
AT1 IN BALANCING CARDIOVASCULAR
SYSTEM
ACE2 demonstrates the key role in the modulation of the RAS in health
and disease, and essentially catalyzes the conversion of angiotensin II
(Ang II) to Ang Hepapeptide-(1–7) (Vickers et al., 2002; Zisman, Meixell,
Bristow, & Canver, 2003) that regulates Ang II activities and also forms in
myocardial circulation and reduces when formation of Ang II is
suppressed. The major generation of Ang-(1–7) in heart is depending on
availability of Ang II. Ang II is a preference substrate for Ang-(1–7)-forming
enzymes which shows a key role in the formation and regulation of Ang-
(1–7). Formation of Ang-(1–9) is confirmed by ACE2, via hydrolyzation
Ang I and also Ang-(1–7) from Ang II and selective ACE inhibitors do not
inhibit these pathways. ACE2 demonstrates more affinity for Ang II
hydrolysis compared to Ang I (Vickers et al., 2002). Moreover, in heart
ventricular, ACE2-mediated virtually all Ang(1–7) formation from Ang II
(Zisman, Keller, et al., 2003). The pathway is shown in Figure 1.
Ang II has a high affinity to two main types of receptors, namely,
Ang II type 1 (AT1) and Ang II type 2 (AT2) receptors (Daviet
et al., 1999; De Gasparo, Catt, Inagami, Wright, & Unger, 2000; Nouet
et al., 2004). AT2-receptor stimulation leads to antagonize the signal-
ing in accordance with stimulation of AT1-receptor. Since there is no
difference between the binding affinity of Ang II for the AT1 and AT2
receptor, stimulation of AT2-receptor demonstrates the same action
of AT1-receptor blockers (ARBs) (Dzau, 2005). The RAS and Ang
II/AT1 receptor axis is shown in Figure 2.
F IGURE 1 Angiotensin peptide pathway. ACE, angiotensin
converting enzyme [Colour figure can be viewed at
wileyonlinelibrary.com]
F IGURE 2 The RAS and Ang II/AT1 receptor axis [Colour figure
can be viewed at wileyonlinelibrary.com]
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However, the latest research shows that Ang-(1–7) has the most
important activity in RAS. Ang-(1–7) causes vasodilation that antago-
nizes AT1-receptor stimulation-mediated vasoconstriction. These conse-
quences reveal to be mediated by the bradykinin–nitric oxide pathway
(Brosnihan, Li, & Ferrario, 1996; Ferrario, Chappell, Tallant, Brosnihan, &
Diz, 1997). So, Ang-(1–7) results in reduction of blood pressure and
exhibits an organ-protective activity such as cardioprotective activity in
diabetic rats (Ebermann et al., 2008) and reduction of cardiac hypertro-
phy, fibrosis, and renal damage (Yamamoto et al., 2006). On the other
hand, Ang-(1–7) potentiates bradykinin, through AT2-receptor- or
through ACE inhibitors (Gorelik, Carbini, & Scicli, 1998). Recent research
on the function of ACE2 suggests that ACE2 has a main role in the
severity of lung failure, for instance, in acute lung injury or in acute
respiratory distress syndrome (ARDS) (Imai, Kuba, & Penninger, 2008).
So, SARS-CoV-2 uses ACE2 as a key receptor for cell fusion and for
in vivo infections, it seems that ACE2 is one of the etiological factors
causing these pathological changes (Kuba, Imai, Rao, Jiang, &
Penninger, 2006). In the ARDS pathogenesis, ACE upregulates Ang II
and can cause severe lung failure through AT1 receptor (Imai
et al., 2005). Besides, SARS-CoV-2 leads to ACE2 downregulation,
which shows an important role in severe acute lung injury in SARS
(Kuba et al., 2005). Finally, in acute lung injury, Ang II, ACE, and AT1
receptor function as lung-injury-promoting factors (Danilczyk, Eriksson,
Oudit, & Penninger, 2004; Imai et al., 2005; Vickers et al., 2002). These
outcomes illustrate not only ACE2 activity has a main function in CVD
but it also causes damage or dysfunctions of other organs.
4 | NARURAL PRODUCTS WITH
POTENTIAL PHARMACOLOGICAL EFFECTS
IN CVD SYMPTOMS OF COVID-19
Disease treatment with natural products is getting popular all over the
world and naturally occurring agents are widely used for complemen-
tary therapy of various ailments. Raising public knowledge and scientific
attention have directed studies toward the function of natural products
in health promotion and disease treatment. Natural products, including
nutraceuticals, can have a great effect on the treatment of cardiovascu-
lar burdens of COVID-19, as evidenced by epidemiological, experimen-
tal and clinical studies (Shukla et al., 2010). In the following sections,
the effects of natural products on AT1 receptors, ACE, and ACE2 and
the compounds that mimic adenosine activity are discussed.
5 | NATURAL PRODUCTS THAT HAVE A
DIRECT IMPACT ON AT1 RECEPTOR
5.1 | The effect of plant products on AT1 receptor
5.1.1 | Guazuma ulmifolia
Bioactive oligomeric and polymeric proanthocyanidins, which include
(-) -epicatechin units, were isolated from the acetone extract of
Guazuma ulmifolia Lam plant. These compounds were used to inhibit
the binding of Ang II to the AT1 receptor (Table 1). Alteration of the
[3H]-Ang II binding was concentration-dependent and related to
the degree of polymerization of various parts containing
proanthocyanidins which are the most active material corresponding
to the polymerized proanthocyanidins. The relation between Ang II
and AT1 receptor binding might be supposed as a potentially biological
activity of proanthocyanidins provides the very broad-spectrum bio-
logical activities of the condensed tannins (Caballero-George
et al., 2002). So it is possible that other highly polymerized
proanthocyanidins or condensed tannins in plants, such as Malus
sylvester (Guyot, Doco, Souquet, Moutounet, & Drilleau, 1997), brown
soybean (Takahata, Ohnishi-Kameyama, Furuta, Takahashi, &
Suda, 2001), horse chestnut (Kimura et al., 2011), and persimmon
(S.-F. Xu, Zou, Yang, Yao, & Li, 2012) might be effective on blocking
the AT1 receptors and need further investigations.
5.1.2 | Qiliqiangxin
Traditional Chinese drug qiliqiangxin, which has been developed via
the meridian theory (W. Liu et al., 2012), can amend urine volume, car-
diac function, and subjective symptoms in patients with chronic heart
failure (Xiao, Song, Li, Liao, & Chen, 2009). Qiliqiangxin consists of
11 distinct combined herbs, including Astragalus sp. radix, ginseng
radix and rhizome, Descurainiae lepidii semen, Alismatis sp. rhizome,
Polygonati odorati rhizome, Aconiti lateralis radix preparata, Salvia
miltiorrhiza radix and rhizome, Cinnamomi ramulus, carthami flos, peri-
ploca cortex, and Citri reticulatae pericarpium (Tao et al., 2015). Based
on a study conducted by Duan et al. (2018), Western blot analysis
showed that qiliqiangxin remarkably decreased the expressions of
non-phagocytic cell oxidase 2, AngII, and B-cell lymphoma 2 (Bcl-2)
associated X protein (Bax), and enhanced the expressions of ATR1
and Bcl-2 in the kidney. Qiliqiangxin remarkably decreased the level
of apoptosis in kidney, which was induced by myocardial infarction.
Altogether, qiliqiangxin might be a potentially efficient drug for the
treatment of cardiorenal syndrome via regulating inflammatory/oxida-
tive stress signaling. Considering these results, qiliqiangxin is an auspi-
cious agent to treat the cardiac effects of COVID-19.
5.1.3 | Carthamus tinctorius
Carthamus tinctorius L., a member of the family Asteraceae, is widely
used in folk medicine and as a beverage in Asian countries (Dajue &
Mündel, 1996). The effects of C. tinctorius extract on vascular remo-
deling, hemodynamics, RAS, and oxidative stress on hypertensive rat
model were studied by Dajue and Mündel (1996). This experiment
showed that C. tinctorius extract suppressed activation of RAS, involv-
ing elevated ACE activity, Ang II level and upregulated expression of
aortic AT1 receptor protein. These findings suggest that C. tinctorius
extract may involve in RAS inhibitory activity and have a potent anti-
oxidant activity (Bunbupha et al., 2018). In general, such a study sug-
gests the potential use of C. tinctorius in the prevention and treatment
of cardiovascular and renal sequels of COVID-19.
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TABLE 1 The pharmacological activity of natural products for the management of cardiovascular symptoms
Natural products Mechanisms Study types References
Guazuma ulmifolia (Oligomeric and
polymeric proanthocyanidins)




Resveratrol Suppresses the Ang II/AT1 receptor axis
and increases the AT2 receptor/Ang
1–7/Mas receptor axis
In vivo (mouse model) (Jang et al., 2018)
Ginsenoside Rb1 Attenuates myocardial fibrosis and
cardiac hypertrophy and decreases the
levels of β-myosin heavy chain, atrial
natriuretic factor, collagen I, periostin,
Ang II, ACE, and AT1 receptor
In vivo (rat model) (Zheng et al., 2017)
Qiliqiangxin (Traditional Chinese drug
contains 11 herbs)
Decreases the expressions of non-
phagocytic cell oxidase 2, AngII, and
Bax, and enhances the expressions of
ATR1and Bcl-2 in the kidney
In vitro (Duan et al., 2018)
Carthamus tinctorius L. Suppresses activation of RAS, involving
elevated ACE activity, Ang II level and
upregulates expression of aortic AT1
receptor protein
In vivo (rat model) (Bunbupha et al., 2018)
Ocimum sanctum L. Inhibits ACE in a concentration-
dependent manner
In vitro (Chaudhary, Nema, Maity,
Bahadur, & Mukherjee,
2013)
Vitis vinifera (Flavan-3-ols) Inhibits ACE In vitro (Fernandez & Labra, 2013)
Moringa oleifera (Niazimin-A,
niaziminin-B and niazicin-A)
Targets ACE via antihypertensive activity Computational study (Khan, Jaiswal,
Kulshreshtha, &
Khan, 2019
Peptide from hydrolysation of a peach
seed
Inhibits ACE and reduces systolic blood
pressure
In vivo (rat model) (Vasquez-Villanueva,
Orellana, Marina, &
García, 2019)
Gelatin of milkfish Inhibits ACE In vitro (Huang, Tsai, Hong, Hsieh,
& Huang, 2018)





Inhibits ACE concentration-dependently In vitro (Anesini, Ferraro, &
Filip, 2008)
Fucus spiralis (Phlorotannins) Inhibits ACE especially in patients with
high blood pressure




Inhibits ACE and shows with anti-
hypertensive activities along with
scavenging potential radical- capacities
Ex vivo (Chakraborty, Krishnan, &
Joy, 2019)
Rheum officinale Baill, Polygonum
multiflorum Thunb., and Polygoni
multiflorum Thunb. (Anthraquinone
and emodin)
Blocks S protein and ACE2
concentration-dependently
In vitro (Ho, Wu, Chen, Li, &
Hsiang, 2007)
Soybean (Glycine max) Inhibits rhACE2 In vitro (Takahashi, Yoshiya,
Yoshizawa-Kumagaye, &
Sugiyama, 2015)
Green tea (Japan), black tea (India) and
Rooibos tea (South Africa)




(Persson, Persson, Hägg, &
Andersson, 2010)
Huayu Tongluo herbs (Traditional
Chinese drug radix and rhizome
Salviae Miltiorrhizae, rhizome of
Chuanxiong, Pheretima, Quanxie
and Shuizhi)
Lowers urinary protein and promotes the
ACE2-Ang-(1–7)-Mas axis, via
upregulating the mRNA and enhancing
protein expression of ACE2 and Mas
In vivo (rat model) (J. Xu et al., 2014)
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5.2 | The effect of active compounds on AT1
receptor
5.2.1 | Resveratrol
Jang et al. (2018) evaluated the effect of resveratrol for the RAS in
aging kidneys. Eighteen mice were separated into two groups the pla-
cebo group and the resveratrol-treated group. Resveratrol-treated
mice showed a better renal function and decreased albuminuria, with
improved renal histological findings compared to a placebo group. The
improvements included decreased in expression of collagen IV, nico-
tinamide adenine dinucleotide phosphate oxidase (NADP),
3-nitrotyrosine, 4,8-hydroxy-20-deoxyguanosine, and fibronectin,
whereas the expression of superoxide dismutase 2 and endothelial
nitric oxide synthase was enhanced (Jang et al., 2018). Resveratrol
also repressed the Ang II/AT1 receptor axis and increased the AT2
receptor/Ang 1–7/Mas receptor axis. These findings displayed that
resveratrol shows preventative results on aging kidneys by decreasing
oxidative stress, inflammation, and fibrosis, via Ang II suppression and
Mas receptor activation (Jang et al., 2018). Altogether, resveratrol dis-
played suppression of Ang II/AT1 receptor axis through various mech-
anisms. This compound may represent a valuable candidate for the
discovery and development of new antiviral drug to combat coronavi-
rus infections.
5.2.2 | Ginsenoside Rb1
The ginsenoside Rb1 has been isolated from Panax notoginseng as one
of the major active compounds (M. Liu & Zhang, 1995). This com-
pound rehabilitated the cardiac cells in heart failure. H-ginsenoside
Rb1 attenuated myocardial fibrosis, cardiac hypertrophy and also
decreased the levels of β-myosin heavy chain, atrial natriuretic factor,
collagen I, periostin, Ang II, ACE, and AT1 receptor. In addition,
ginsenoside Rb1 might restitute cardiac/mitochondrial function via
the Akt, extracellular-signal-regulated kinase (ERK), and transforming
growth factor-β1 (TGF-β1)/Smad signaling pathways (Zheng
et al., 2017). This indicates the possible application of ginsenoside
Rb1 for COVID-19 infection-related cardiac effects.
6 | NATURAL PRODUCT THAT HAS A
DIRECT ACE-INHIBITORY IMPACT
6.1 | Ocimum sanctum
Ocimum sanctum L. is used in several ancient systems of traditional
medicine, such as Ayurveda, Greek, Roman, Siddha, and Unani (Gupta,
Prakash, & Srivastava, 2002). In the study performed by Chaudhary
et al. (2013), leaves, oil, and ethyl acetate fractions of O. sanctum as
well as pure compound eugenol demonstrated ACE-inhibitory activity
in a concentration-dependent manner. O. sanctum extract/fractions,
oil, and eugenol inhibited ACE and exhibited antihypertensive action.
Therefore, the authors concluded that O. sanctum may be useful in
the inhibition of CVD-related to ACE activity and might have a pros-
perous future in the prevention and treatment of cardiovascular
sequels of COVID-19.
6.2 | Grapes and wines
Several studies revealed the antiviral properties of grapes and wines
(Bekhit et al., 2011; Konowalchuk & Speirs, 1976). Flavan-3-ols from
red grape seeds and skin extracts with high proanthocyanidins
showed ACE-inhibitory activities and raw seed and skin extracts
inhibited over 80% of ACE activity. However, the purified seed and
skin extracts lost their ability to inhibit ACE after intestinal digestion
(Fernandez & Labra, 2013). As an antiviral extract, grape extract can
be considered as a source of antiviral compounds. The findings indi-
cate that the inhibitory effect of red grape seed and skin extracts on
ACE may have therapeutic potential and these extracts may be useful
for the treatment of COVID-19-related CVDs.
6.3 | Moringa oleifera
In W. Liu et al. (2012) study,Moringa oleifera demonstrated an antiviral
activity against a newcastle disease virus in ovo. Several isolated com-
pounds from M. oleifera, namely niazimin-A, niaziminin-B, and
niazicin-A, were reported to exhibit potent antihypertensive activities
TABLE 1 (Continued)
Natural products Mechanisms Study types References
Chinese yam Ameliorates LPS-induced cardiac
contractility via the deterrence of RAS
and apoptosis possibly through an ER-
SHC/RAS/Raf1-dependent
mechanisms
In vitro and in vivo (rat model) (Zeng et al., 2019)
1-Methylisoguanosine Stimulates adenosine-sensitive adenylate
cyclase, cardiovascular responses and
skeletal muscle and function as a long-
acting adenosine analogue
In vivo (mouse model) (Baird-Lambert, Marwood,
Davies, & Taylor, 1980)
Abbreviations: ACE, angiotensin converting enzyme; ACE2, angiotensin converting enzyme 2; Ang II, angiotensin ll; AT1, angitensin ll type 1 receptor; AT2,
angitensin ll type 2 receptor; Bcl-2, B-cell lymphoma; LPS, lipo-poly saccharide ; rh ACE2, Rhesus angiotensin converting enzyme 2.
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through targeting ACE. According a study conducted by Khan
et al. (2019), these molecules computationally have shown greater
energy for better binding than standard drugs, which previously
known for inhibition of ACE and can act as a great pharmacophore for
in vitro and in vivo research in the development of potent drugs. Alto-
gether, according to these results, isolated compounds from
M. oleifera are good choices for evaluating the impacts of these natu-
ral compounds on the cardiovascular symptoms of COVID-19.
6.4 | Peach seed
A peptide fraction from hydrolyzed peach seed revealed high ACE-
inhibitory activity. Vasquez-Villanueva et al. (2019) demonstrated that
this peptide fraction containing isoleucine-tyrosine-serine-proline-
histidine (IYSPH) showed the highest capacity for inhibition of ACE.
Cytotoxic effects of peptides were demonstrated in three different
cell lines, namely HeLa, HT-29, and HK-2. Oral administration of
peach seed peptide fraction or peptide IYSPH led to a remarkable sys-
tolic blood pressure reduction in spontaneously hypertensive rats.
The systolic blood pressure reduction and ACE-inhibitory properties
of peach seed peptide fraction may increase the host's defense
against COVID-19 infection. However, the underlying mechanisms
are not clear and require future evaluation.
6.5 | Fish gelatin
Huang et al. (2018) isolated fish gelatin from nonextruded milkfish
scale and extrusion-pretreated milkfish scale. The extracted gelatins
were hydrolyzed to yield four different hydrolysates. In addition,
these hydrolysates showed ACE-inhibitory activities (Huang
et al., 2018). Further research is needed to explore the safety and effi-
cacy of this natural supplement in food and nutraceutical products in
controlling the cardiovascular symptoms of coronavirus.
6.6 | Camellia sinensis
Camellia sinensis exhibits various pharmacological effects on the cardio-
vascular system, including antioxidative (Anesini et al., 2008), antip-
roliferative (Santos et al., 2018), anti-angiogenic (Rashidi, Malekzadeh,
Goodarzi, Masoudifar, & Mirzaei, 2017), and nitric oxide (NO) synthase-
activating properties (Siamwala et al., 2013). In a study executed by
Persson, Josefsson, Persson, and Andersson (2006), purine alkaloids
and main flavanols present in green and black tea were evaluated for
their effects on ACE and NO in human umbilical veins cultured endo-
thelial cells. According to the results, a concentration-dependent and
significant inhibition of ACE activity was observed for both green and
black tea. In addition, (-)-epicatechin, (-)-epigallocatechin, (-)-epi-
catechingallate, and (-)-epigallocatechingallate inhibited the ACE con-
centration dependently. In conclusion, tea extracts from C. sinensis may
have the potential effect to prevent and protect against CVD and may
increase the host's defense against coronavirus infection; however, the
scientific confirmation is lacking.
6.7 | Fucus spiralis
Recently, algae have received much attention as a natural source of
ACE inhibitors, such as the phlorotannins that are principal polyphe-
nols in brown algae (Wijesekara & Kim, 2010). The study of Paiva
et al. (2016) reports ACE inhibition by brown algae Fucus spiralis.
Studies have shown that F. spiralis can be a potent source of ACE
inhibitors with a great effect on public health, especially in patients
with high blood pressure and can also be useful for cardiovascular
effects of COVID-19 infection.
6.8 | Amphioctopus neglectus
Amphioctopus neglectus (family: Octopodidae) is known as a delicious
seafood in many cultures, especially in the Mediterranean and Asian
coasts. Macrocyclic lactones isolated from A. neglectus demonstrated
potential radical-scavenging property and antihypertensive activity via
inhibiting ACE. Chakraborty et al. (2019) showed the protective effect
of the separated macrocyclic lactones was mediated by augmentation
of antioxidant systems, which subsequently reduced the hypertension-
related disorders. So, in viral infections like COVID-19, promising
effects may be expected from A. neglectus through inhibition of ACE.
7 | NATURAL PRODUCTS WITH A DIRECT
ACE-2-INHIBITORY IMPACT
7.1 | Polygonaceae family
Three Chinese medicinal plants from the Polygonaceae
family inhibited S protein of COVID-19 and ACE2. The half-maximal
inhibitory concentration (IC50) value for Rheum officinale Baill. root
tubers, Polygonum multiflorum Thunb., and the root tubers, caulis and
vines of P. multiflorum, ranged from 1 to 10 μ/ml. Based on a study by
Ho et al. (2007), anthraquinone and emodin, two compounds isolated
from genus Rheum and Polygonum, remarkably blocked the S protein
and ACE2 interaction in a concentration-dependent manner. These
findings suggest that emodin could be considered as a potential lead
therapeutic agent for the treatment of COVID-19 infection.
7.2 | Soybean
According to a study conducted by Takahashi et al. (2015), soybean
(Glycine max) showed rhACE2 inhibitory effect. Based on results of
Takahashi et al., the active ingredients of G. max that identified as
ACE2iSB, strongly inhibited rhACE2 activity with an IC50 value of
84 nM (Takahashi et al., 2015). Hence, G. max can be used as
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nutraceuticals for managing the cardiovascular sequels of coronavirus
infection; however, further clinical investigations are warranted.
7.3 | Camellia sinensis, Camellia sinensis var.
assamica, and Aspalathus linearis
Persson et al. (2010) investigated the effects of Camellia sinensis (green
tea), Camellia sinensis var. assamica (black tea), and Aspalathus linearis
(Rooibos tea) in reducing the patients' mortality from CVD. Additionally,
the effect of three different kinds of tea, such as green tea (Japanese Sen-
cha), black tea (India Assam Broken Orange Pekoe), and Rooibos tea
(South Africa) have been investigated on the ACE and NO in a random-
ized, three-phase, crossover study. According to the results, oral adminis-
tration of one dose of Rooibos tea and green tea remarkably inhibited
ACE activity 60 min after administration of the tea. Although, no substan-
tial effect on NO concentration was observed. These results offer that
green tea and Rooibos tea with ACE inhibitory activity revealed cardio-
vascular protective activity (Persson et al., 2010) and also might cover the
cardiovascular symptoms of COVID-19, which needs further evaluation.
7.4 | Huayu Tongluo herbs
Evaluating the effect of Huayu Tongluo herbs, which is consisted of
the combination of radix and rhizome of Salviae Miltiorrhizae, rhizome
of Chuanxiong, Pheretima, Quanxie (Scorpio), and Shuizhi (Hirudo)
(Pan, Chen, Ma, Guo, & Jia, 2013) on ACE-2 -Ang-(1–7)-Mas axis, has
demonstrated renal protection in diabetic nephropathic rats.
According the study of J. Xu et al. (2014), these Chinese herbs
lowered urinary protein and promoted the ACE2-Ang-(1–7)-Mas axis
via upregulating the mRNA and enhancing protein expression of
ACE2 and Mas. Therefore, the results encourage the use of these Chi-
nese herbs for the treatment of viral diseases like COVID-19.
8 | NATURAL PRODUCTS THAT MIMICS
ADENOSINE ACTIVITY
The remdesivir (10-cyano-substituted adenosine nucleotide), is a
prodrug that is derived from nucleotide (Agostini et al., 2018),
exhibited broad-spectrum antiviral activity against plenty of RNA
viruses in particular coronavirus via blocking RNA-dependent
RNA polymerase (Tchesnokov, Feng, Porter, & Götte, 2019). These
classes of compounds may have therapeutic impact on COVID-19.
Therefore, the natural products that mimic adenosine activity or hav-
ing the similar structure are discussed in following section.
8.1 | Chinese yam
Zeng et al. (2019) carried out the study to evaluate the impact of Chi-
nese yam extract and adenosine on lipopolysaccharide (LPS)-induced
cardiac anomalies and associated mechanism of action. Based on
results, the Chinese yam extract and adenosine led to amelioration of
heart function, downregulation of proinflammatory cytokines, sup-
pression of RAS and mitogen-activated protein kinases (MAPK), inhi-
bition of apoptosis markers, and elevation of estrogen receptor
(ER) and SHC/Ras/Raf1 expression. Finally, it was evident that Chi-
nese yam extract along with adenosin improved LPS-induced cardiac
contractility via inhibition of RAS and apoptosis possibly through an
ER–SHC/Ras/Raf1-dependent mechanism (Zeng et al., 2019). In sum-
mary, Chinese yam extract in conjunction with adenosin may be effec-
tive to treat cardiovascular ailments of viral diseases like COVID-19.
8.2 | 1-Methylisoguanosine
1-Methylisoguanosine, a marine secondary metabolite, is isolated
from marine sponge Tedania digitate. It has skeletal muscle relaxant,
cardioprotective, and hypothermic effects. The cardioprotective
effects of this compound are similar to those of adenosine. A
series of 1-methylisoguanosine analogs has been evaluated
through structure-activity studies, and it has been suggested that
there is a direct connection between the compounds' ability to stim-
ulate adenosine-sensitive adenylate cyclase and cardiovascular
responses and skeletal muscular effects. Thus, it appears that
1-methylisoguanosine may function as a long-acting adenosine ana-
log (Baird-Lambert et al., 1980). Finally, due to the importance of
pure compounds in combating coronavirus, 1-Methylisoguanosine
could pave the road for identifying novel antiviral agent for the
treatment of SARS-CoV-2infection.
9 | CONCLUSIONS AND FUTURE
DIRECTION
Natural compounds can demonstrate a synergy along with pharmaco-
logical treatments in several kinds of pathologies (Di Lodovico
et al., 2019). Due to the prevalence of COVID-19 disease, there is an
instant quest for safe, efficient, and relatively low-cost new drug can-
didates. Evidence from in vitro and in vivo studies suggests that the
medicinal plants and natural products discussed in this review signifi-
cantly modified various molecular, cellular, and metabolic mechanisms
that control both cardiovascular pathogenesis and COVID-19-related
cardiovascular symptoms. In this review, the medicinal value of natural
products on CVDs and COVID-19 has been presented in Table 1 and
summarized in Figure 3. Emerging evidence clearly demonstrates that
these herbal medicines have strong therapeutic properties and can
improve pathological conditions related to CVDs and coronavirus-
inflicted cardiovascular symptoms. However, proven clinical therapeu-
tic benefits of these natural agents have not yet been realized yet.
Hence, treatment using these natural agents cannot be initiated with-
out further studies. Further, the safety and toxicity of various natural
products have not been established. We conclude that well-designed
preclinical studies and clinical trials involving larger sample sizes are
MOHAMMADI POUR ET AL. 7
needed to investigate the role of different natural products and their
underlying mechanisms in the context of COVID-19-related CVDs.
Furthermore, the safety and toxicity of these natural products should
be evaluated by future clinical trials.
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